Abstract:In order to discover antiplatelet drugs with novel structures and expand our research scope, total twenty 1,3-benzenedisulfonyl piperazines, were designed and synthesized. These target compounds were divided into two series, namely 4-methoxy-1,3-benzenedisulfonyl piperazines of series 1 and 4-ethoxy-1,3-benzenedisulfonyl piperazines of series 2. With adenosine diphosphate (ADP), arachidonic acid (AA) and collagen as inducers, respectively, the Born turbidimetric method was used to screen the anti-platelet activity in vitro of all target compounds at a concentration of 1.3 μM, aspirin and picotamide as positive control drugs. And of which, the activity of five compounds for collagen was higher than both picotamide and aspirin. In ADP or AA channel, compounds with an inhibition rate greater than 33% were selected, and their corresponding IC50 values were obtained. According to the IC50, the in vitro activity of one compound for ADP was higher than picotamide, and for AA, two compounds were higher than two positive control drugs and other two compounds only higher than or equal to aspirin. Completed the preliminary analysis of the structure-activity relationship of the compound involved in this study. Further, eight compounds exhibiting the high activity in one or two test channels, were subjected to cytotoxicity test on mouse fibroblasts (L929) by CCK-8 method. The in vitro cytotoxicity of most test compounds showed less than or same to control drug picotamide at 10 μM, but at the higher concentration of 100 μM, merely two compounds exhibited higher cell survival rate than that of picotamide. In addition, compound N1, N3-di (4-ethoxy-1, 3-benzenedisulfonyl)bis(1-(m-tolyl)piperazine), which is delivery activity in the three test channels, and compound N1, N3- di (4-methoxy-1, 3-phenylenedisulfonyl)bis(1-(m-tolyl)piperazine), which is the lowest cytotoxic in vitro compound among series 1 and series 2, respectively, are found and selected for simulation analysis as two most likely to dock with the receptor P2Y12. Each of synthesized compounds in silico molecular property and ADME (absorption, distribution, metabolism and excretion) are predicted by using Molinspiration property engine v2018.10 and PreADMET online servers, respectively. Compared with other series of compounds in the previous stage, the two series compounds obtained after the introduction of piperazinyl have a similar in vitro activity.

Synthesis of Novel 3-Butylphthalide Derivatives Containing Isopentenylphenol Moiety as Potential Antiplatelet Agents for the Treatment of Ischemic Stroke

Novel brain-targeting 3-n-butylphthalide prodrugs for ischemic stroke treatment

Novel Hybrids of 6-Amino-3-n-butylphthalide and Neuroprotective Groups against Ischemic Stroke

Dl-3-N-Butylphthalide Inhibits Platelet Activation Via Inhibition Of Cpla2-Mediated Txa(2) Synthesis And Phosphodiesterase

Synergistic effects and molecular mechanisms of DL-3-n-butylphthalide combined with dual antiplatelet therapy in acute ischemic stroke

Design, synthesis, and evaluation of n-butylphthalide and ligustrazine hybrids as potent neuroprotective agents for the treatment of ischemic stroke in vitro and in vivo

Synthesis and bioevaluation of Scutellarein-Tertramethylpyrazine hybrid molecules for the treatment of ischemic stroke

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

Annexin V‐modified platelet‐biomimetic nanomedicine for targeted therapy of acute ischemic stroke

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke

Synthesis and biological evaluation of N 6 derivatives of 8-azapurine as novel antiplatelet agents

Biopharmaceutical, preclinical pharmacokinetic and pharmaco-dynamic investigations of an orally administered novel 3-nbutylphthalide prodrug for ischemic stroke treatment

Discovery of orally bioavailable phenyltetrazolium derivatives for the acute treatment and the secondary prevention of ischemic stroke

Synthesis, characterization and thrombolytic activity evaluation of novel pyrazolo[3,4- b ]pyridine-4-carbohydrazide derivatives

Platelet bio-nanobubbles as microvascular recanalization nanoformulation for acute ischemic stroke lesion theranostics

Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents

Development of Benzimidazole Derivatives as Novel Anti-platelet Drugs

Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents

A neurovascular dual-targeting platelet-like bioinspired nanoplatform for ischemic stroke treatment

Synthesis and evaluation of L-quebrachitol derivatives against platelet aggregation